No Survival Benefit from Adding Adjuvant Chemotherapy to Endocrine Therapy in Older Women with a Genomic Grade Index High-Risk ER-positive, HER2-negative Breast Cancer By Ogkologos - August 19, 2025 412 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ASTER 70s study Source RELATED ARTICLESMORE FROM AUTHOR Patient Guide in Testicular Cancer Now Available Also in Italian Adding 177Lu-PNT2002 to SBRT Significantly Improves PFS in Patients with Oligorecurrent Hormone-Sensitive Prostate Cancer A Short-Course Dose Escalation Strategy Could Improve Ability to Reach Target Dose of Adjuvant Abemaciclib in High-Risk Early-Stage HR-positive, HER2-negative Breast Cancer MOST POPULAR EMA Recommends Extending the Indications for Dostarlimab October 17, 2023 Cancer Patients Have Been Lonelier During the COVID-19 Pandemic May 27, 2021 What’s at the Root of Ovarian Cancer? New Study May Have... April 24, 2025 New Class of Compounds Rewires Cancer Cells to Self-Destruct August 29, 2023 Load more HOT NEWS Exosomes May Help Tumors Evade Immune System Her Mother Died of Breast Cancer When She Was Five. 16... The Gift of Time Mortality From PSA-Detected Localised Prostate Cancer Remains Very Low Regardless of...
